#

Key takeaways

• Regina Barzilay and James Collins received the 2026 Pritzker Prize for AI in Science Research Excellence.

• The award recognizes work that combines deep learning, bioengineering, and experimental validation.

• Their research identified antibacterial candidates against drug-resistant pathogens.

• The prize is associated with the University of Chicago and Caltech and was established in 2024.

• The recognition is for research, not for a newly approved antibiotic or patient treatment.

MIT researchers receive the 2026 Pritzker Prize

MIT News reported on November 2, 2026, that Regina Barzilay and James Collins received the 2026 Pritzker Prize for AI in Science Research Excellence. The award recognizes their work combining deep learning, bioengineering, and experimental validation to identify antibacterial candidates against drug-resistant pathogens. It is jointly associated with the University of Chicago and Caltech, and it was established in 2024.

Barzilay is MIT's School of Engineering Distinguished Professor of AI and Health. Collins is MIT's Termeer Professor of Medical Engineering and Science. They are faculty co-leads of the Abdul Latif Jameel Clinic for Machine Learning in Health. They are also affiliated with MIT's computing and engineering organizations.

What the research found

The source highlights two major research milestones. In 2020, Barzilay and Collins, with first author Jonathan Stokes, published a Cell paper describing halicin. They identified it using a deep learning model trained on 2,500 molecules. Halicin had previously been studied as a possible diabetes drug. The research found antibacterial activity against several resistant pathogens.

In 2023, the collaborators used machine learning to identify abaucin. The source describes abaucin as a narrow-spectrum candidate active against Acinetobacter baumannii. These findings show how the team used AI methods to search for antibacterial candidates. The prize recognizes that body of work.

Research-stage progress, not a clinical announcement

The fresh news is recognition of this research, not a newly approved antibiotic or a treatment available to patients. That distinction matters. The award recognizes scientific work. It is not evidence of regulatory approval or availability to patients.

Collins describes AI's progression from finding candidates toward molecular design. That framing suggests a broader shift in how AI supports drug discovery. The source does not claim that this shift is complete. It presents it as an ongoing direction of research.

Barzilay adds an important caution. She says existing AI automates only portions of drug discovery. She also notes that realistic models of human biology remain difficult to build. This keeps the work in context. The research is promising, but it still depends on experimental validation and further scientific development.

Why the award matters

The prize draws attention to a specific kind of AI research. It rewards work that links computational methods with laboratory validation. In this case, the focus is on antibacterial discovery against drug-resistant pathogens. The source presents the award as recognition of a research program, not a product launch.

The timeline also matters. The 2020 Cell paper on halicin and the 2023 abaucin work are separate discoveries. The 2026 prize recognizes the broader contribution across those efforts. That helps distinguish the scientific results from the later award.

Bottom line

Barzilay and Collins were recognized for AI-enabled antibiotic discovery research that combined deep learning, bioengineering, and experimental validation. Their work identified halicin and abaucin as antibacterial candidates in separate studies. The 2026 prize honors that research path, and should be distinguished from clinical testing, regulatory approval and availability to patients.